STAGE IV RENAL CELL CANCER AJCC V8

This early-stage trial explores whether a ketogenic (low-carb, high-fat) diet can make immunotherapy more effective for people with advanced melanoma or kidney cancer. About 60 participants will follow the diet while receiving standard immunotherapy drugs. The main goals are to c…

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes a…

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in adults with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the disease. About 65 particip…

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…

This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…

This study tests whether focused, high-dose radiation (SBRT) can control kidney cancer that has spread to a few spots in the body. The goal is to see if radiation alone can delay or avoid the need for strong drugs (systemic therapy). About 123 people with metastatic kidney cancer…

This early-stage trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and effective for people with advanced kidney cancer. About 31 participants will receive the combination to see if it improves gut bacteria linke…

This study tests whether keeping blood pressure very low (below 120 mmHg) is safer and more effective than the usual target (below 140 mmHg) for people with advanced kidney or thyroid cancer starting certain targeted therapies. About 61 participants will be followed for 6 months …

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in 59 people with advanced solid tumors, including melanoma, colorectal, ovarian, and k…

This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 adults with this condition will receive either the combination or cabozantinib alone. The goal is …

This study tests two treatment options for people with advanced kidney cancer that has spread and continued to grow after immunotherapy. One group gets a combination of two drugs (lenvatinib and everolimus), while the other gets a single drug (cabozantinib). The goal is to see wh…

This study tests whether giving precise, high-dose radiation to a few cancer spots before starting standard drug therapy helps people with kidney cancer that has spread to 2-5 places live longer. About 472 adults with this condition will either receive radiation plus standard dru…

This study tests whether adding the drug ixazomib to standard chemotherapy (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in people with a rare and aggressive kidney cancer called renal medullary carcinoma. About 30 patients with advanced or spreading d…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib works better than cabozantinib alone for people with advanced papillary kidney cancer that has spread. About 200 participants will receive either the combination or the single dr…

This early-phase study tests whether adding a gut bacteria supplement (CBM588) to standard drugs (cabozantinib and nivolumab) can improve treatment for advanced kidney cancer. About 31 adults with metastatic kidney cancer will take the supplement along with their regular therapy.…

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This study tests whether a smartphone app that teaches mindfulness can help people with metastatic kidney cancer feel better emotionally and improve their quality of life. About 21 patients who are already receiving immunotherapy and have moderate to high fear of their cancer ret…